Cargando…

Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy

AIMS: The purpose of this study was to evaluate the effectiveness of a new, fixed, yet individualized dosing regimen of activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in the setting of a life-threatening bleeding in a secondary care c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wójcik, Cezary, Schymik, Michelle L., Cure, Eric G.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840588/ https://www.ncbi.nlm.nih.gov/pubmed/20436891 http://dx.doi.org/10.1007/s12245-009-0125-8

Ejemplares similares

Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
por: Ibarra, Francisco, et al.
Publicado: (2022)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial
por: Sera, Valerie A., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
por: Golestani, Mina, et al.
Publicado: (2016)

Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
por: Tjønnfjord, Geir E, et al.
Publicado: (2007)

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)
por: Negrier, Claude, et al.
Publicado: (2016)

Prothrombin Complex Concentrate for Rapid Reversal of Warfarin Anticoagulation to Allow Neuraxial Blockade
por: Skerritt, Conor, et al.
Publicado: (2014)

Combination of Novoseven and Feiba in Hemophiliac Patients with Inhibitors
por: Malkan, Umit Yavuz, et al.
Publicado: (2018)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
por: Ettingshausen, Carmen Escuriola, et al.
Publicado: (2023)

Using of prothrombin complex concentrate in patients with trauma-induced coagulopathy
por: Tarabrin, O, et al.
Publicado: (2015)

Activated Prothrombin Complex Concentrate for coagulopathy reversal secondary to ischemic hepatic injury due to cardiac tamponade: A case report
por: Mitwally, Hassan, et al.
Publicado: (2021)

Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
por: Chapman, Scott A, et al.
Publicado: (2014)

Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model
por: Dickneite, G., et al.
Publicado: (2009)

Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
por: Maguire, Michelle, et al.
Publicado: (2019)

Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays
por: Bordeleau, Simon, et al.
Publicado: (2015)

Evaluation of fixed dose four-factor prothrombin complex concentrate for warfarin reversal at a level 1 trauma center
por: Drone, H, et al.
Publicado: (2015)

A Rare Case of Skin Necrosis Following Extravasation of Prothrombin Complex Concentrate (PCC) Infusion During Warfarin Reversal
por: Smith, Emma C, et al.
Publicado: (2023)

Prothrombin Complex Concentrates for Coagulopathy in Liver Disease: Single‐Center, Clinical Experience in 105 Patients
por: Drebes, Anja, et al.
Publicado: (2019)

Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses
por: Hannadjas, Ioannis, et al.
Publicado: (2023)

Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
por: Margraf, David J., et al.
Publicado: (2022)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
por: Schultz, Nina Haagenrud, et al.
Publicado: (2017)

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
por: Antunes, S V, et al.
Publicado: (2014)

The effect of fibrinogen and prothrombin complex concentrate on dilutional coagulopathy in a porcine model of uncontrolled hemorrhagic shock
por: Fries, D, et al.
Publicado: (2005)

Comparison of prothrombin complex concentrate and fresh frozen plasma on thrombin generation and hemorrhage in experimental dilutional coagulopathy
por: Dickneite, G, et al.
Publicado: (2008)

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
por: Go, Alan S., et al.
Publicado: (2022)

Reversal of oral anticoagulation with prothrombin complex concentrate (Octaplex)
por: Riess, H, et al.
Publicado: (2007)

3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis
por: Puchstein, Dorothea, et al.
Publicado: (2023)

Correction of haemorrhagic shock-associated coagulopathy and impaired haemostasis by plasma, prothrombin complex concentrates or an activated protein C-targeted DNA aptamer in mice
por: Eltringham-Smith, Louise J., et al.
Publicado: (2023)

Comparing prothrombin complex concentrate and fresh frozen plasma with blood viscosity characteristics in patients with trauma-induced coagulopathy
por: Tarabrin, O, et al.
Publicado: (2015)

Prothrombin, alone or in complex concentrates or plasma, reduces bleeding in a mouse model of blood exchange-induced coagulopathy
por: Eltringham-Smith, Louise J., et al.
Publicado: (2019)

Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience
por: Mačiukaitienė, Jomantė, et al.
Publicado: (2018)

Efficacy and safety of activated prothrombin complex concentrate for the reversal of vitamin K antagonist major bleeding
por: Sheikh-Taha, Marwan, et al.
Publicado: (2022)

The role of prothrombin complex concentrates in reversal of target specific anticoagulants
por: Babilonia, Katrina, et al.
Publicado: (2014)

Reversal of warfarin-coagulopathy: How to improve plasma transfusion practice in a community hospital setting?
por: Munshi, Lubna Bashir, et al.
Publicado: (2019)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018)

Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study
por: Margraf, David J., et al.
Publicado: (2020)

Warfarin Reversal With Four-Factor Prothrombin Complex Concentrate for Left Ventricular Assist Device Conversion Surgery Monitored by TEG6s: A Case Report
por: Ito, Hisakatsu, et al.
Publicado: (2022)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p5o3tkmp43h3pnbtvdc892mkv5